Researcher

Qi Zeng is presently Research Director at A*STAR’s Institute of Molecular Cell Biology (IMCB). She is also Adjunct Professor at the Department of Biochemistry of the National University of Singapore (NUS). Zeng carried out her PhD research at Roswell Park Memorial Institute (RPMI, US) and IMCB and was conferred her PhD degree by NUS in 1993. Later, her team demonstrated that PRL1 and PRL3 monoclonal antibodies inhibit experimental metastatic tumours expressing these antigens. She is a pioneer in using the unconventional approach of immunotherapy to target intracellular oncoproteins for inhibiting tumour growth in mouse models of cancer.